XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation

Phase 2BudiodaronePositive

AI Analysis

Summary

XYRA announced the first patient dosed in Europe for the Phase 2/3 HARBOR-AF study evaluating budiodarone in paroxysmal and persistent atrial fibrillation, using implanted and wearable cardiac monitors to determine optimal dosing.

Clinical Trial Data

Phase

Phase 2/3

Outcome Details

First patient dosed in Europe in Phase 2/3 HARBOR-AF study

Importance:5/10

Sentiment:

0.30

atrial fibrillationphase 2/3cardiac monitoringEuropefirst patient dosed

Related Companies

$WHSI $TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on August 31, 2026 8:00 AM

Read Original